高脂血症时血清二乙基对硝基苯磷酸酯酶活性的变化

目的 :研究tritonWR 13 3 9致小鼠高脂血症时血清二乙基对硝基苯磷酸酯酶 (ParaoxonaseI ,PON 1)活性的变化及PON 1活性与血浆脂质含量之间的关系。方法 :在小鼠尾静脉注射tritonWR13 3 9后的 3h ,6h ,12h ,2 4h ,48h ,72h ,眼球摘除术取血 ,用酶标法测定小鼠血浆总胆固醇 (TC) ,甘油三酯 (TG ) ,高密度脂蛋白 -胆固醇 (HDL -C) ,载脂蛋白AI (ApoAI) ,载脂蛋白B (ApoB含量 ) ,并计算出ApoAI/ApoB ,HDL -C/TC比值 ,用分光光度计法测定PONI活性。结果 :TritonWR 13 3 9尾静脉注射后 3h ,小鼠血浆TC和TG含量即急剧增高 ,与对照组相比 ,P <0 .0 1,分别在注射后 2 4h和 3h达到峰值 ,随后逐渐下降 ,其中血浆TG含量在注射后 48h即恢复正常水平。tritonWR13 3 9尾静脉注射后 3h ,小鼠血浆HDL -C和ApoB含量急剧增高 ,与对照组相比 ,P <0 .0 5,分别在注射后 2 4h和 6h达到峰值 ,随后逐渐下降 ,分别在注射后 48h和 72h恢复正常水平。tritonWR13 3 9尾静脉注射后 3h ,小鼠血浆ApoAI含量即急剧降低 ,与对照组相比 ,P <0 .0 5,随后逐渐增高 ,在注射后 6h即恢复正常水平。tritonWR 13 3 9尾静脉注射后 3h ,小鼠血浆ApoAI/ApoB和HDL-C/TC比值减少 ,与对照组相比 ,P <0 .0 1,随后逐渐增高 ,其中ApoAI/ApoB比值在 72h恢复     

老年高血脂患者Apo C检测的临床意义

目的探讨老年高血脂患者血清载脂蛋白CⅡ、CⅢ(Apo CⅡ、CⅢ)的变化及意义.方法免疫比浊法测定老年不同高血脂组血清Apo CⅡ、Apo C Ⅲ水平,并分析与其他指标的相关性.结果老年高血脂患者血清Tch、LDL水平各组间无差异(P＞0.05),且与TG浓度无明显相关; TG浓度与HDL水平呈负相关关系(r=0.435,P＜0.001),与Apo CⅡ、Apo CⅢ水平呈正相关关系(r=0.478,0.426,P＜0.001):老年高血脂患者血清Apo C Ⅱ、Apo CⅢ水平在男女性别间无显著性差异(P＞0.05).结论血清Apo CⅡ、Apo CⅢ水平与动脉粥样硬化危险因子TG呈正相关,提示其在老年人心血管疾病的发生中起一定的作用.     

不同剂量辛伐他汀对肾病综合征高脂血症的近期疗效

目的 :观察辛伐地他汀 -舒降之对肾病综合征高脂血症的近期疗效及安全性 ,比较不同剂量辛伐他汀的降脂作用。方法 :72例均系肾综合并高脂血症的患者 ,随机分治疗组 (5 6例 )和对照组 (16例 ) ,在积极治疗原发病的同时 ,治疗组给予服辛伐他汀每晚 5～ 2 0mg ,14例混合性高脂血症患者同时服用非诺贝特 ;对照组未用降脂药。观察治疗前及治疗后 1周、2周血脂全套 (TC ,TG ,LDL和HDL)、肝功能 (AST ,ALT ,TP和ALB)、肾功能 (BUN ,Scr)、及尿蛋白定量的变化。结果 :辛伐他汀每晚 2 0mg服用 1周可使 6 3%的患者总胆固醇 (TC)下降 33% ,服用 2周可使 84%的患者血TC降至正常 ;单用辛伐他汀在降低TC的同时 ,可使甘油三酯 (TC)下降 43.16 % ,若与非诺贝特合用可使TG下降达 6 4.2 2 % ,未见不良反应发生 ;辛伐他汀的降脂作用与剂量及用药时间密切相关 ,2 0mg >10mg >5mg ,每晚服用 5mg共 2周仅能使 6 0 %的患者TC下降 12 .5 %。结论 :辛伐他汀 (每晚 2 0mg)能安全、快速有效降低肾病综合征患者的高脂血症 ,而对减少尿蛋白、改善肾功能近期无作用     

Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment

Summary The effect of nifedipine 40 mg·day^–1 for 3 months on glucose tolerance, insulin and C-peptide secretion after an oral glucose tolerance test (OGTT), intra-venous glucose tolerance test (IVGTT) and glucagon stimulatory test, has been studied in 8 moderately hypertensive women suffering from non-insulin dependent diabetes mellitus (NIDDM).No significant variation in glucose metabolism was noted after nifedipine treatment, except for a slight improvement in insulin secretion after OGTT at the end of the study. There was an increase in cholesterol as a collateral effect.     

国产达美康治疗Ⅱ型糖尿病的临床观察

本文应用国产达美康对71例NIDDM患者进行了临床观察,同时以优降糖做对照。结果显示:达美康降糖效果与优降糖相当,降血脂方面优于优降糖,并可降低全血粘度,而对照组无此变化,提示达美康在降低血粘度、改善微循环、防治糖尿病性微血管病变上有它独特的作用。结果表明达美康是治疗NIDDM安全而有效的口服降糖药。     

左旋精氨酸与维生素B6对低密度脂蛋白抑制兔胸主动脉内皮舒张功能的影响

目的观察正常人的低密度脂蛋白(native low density lipoprotein,nLDL),人工氧化的低密度脂蛋白(oxidized lowdensity lipoprotein,ox-LDL)及非胰岛素依赖型糖尿病(Non-insulin dependent diabetes mellitus,MDDM)患者的低密度脂蛋白(diabetic low density lipoprotein,dLDL)对兔胸主动脉环内皮的损伤作用及左旋精氨酸(L-arginine,L-Arg),维生素B6(pyridoxine,VB6)的拮抗效应.方法采用离体动脉环灌流的方法,观察兔胸主动脉环对乙酰胆碱(acetycholine,Ach),钙离子载体A23187的舒张反应.结果3种LDL均抑制动脉环对Ach及A23187的舒张,损伤强度为ox-LDL＞dLDL＞nLDL,并具有浓度依赖性;L-Arg、VB6能明显拮抗LDL的抑制作用,但并不能完全逆转.以SOD作为保护药对照,250 U/ml的浓度能够显著抑制dLDL对内皮的损伤.结论3种低密度脂蛋白主要可能通过降低NO生物活性损伤内皮,L-Arg、VB6具有内皮保护作用.     

Calorie restriction increases serum parathyroid hormone and decreases serum calcitonin levels in patients with maturity onset diabetes mellitus

Calorie restriction is important in managing patients with maturity onset diabetes mellitus (NIDDM). The effect of such restriction on calcium metabolism is not known. The objective of this study was to determine whether patients on calorie restricted diets would show any modification of parathyroid hormone (PTH) and calcitonin (CTN). The serum levels of PTH and CTN were measured by radioimmunoassays in 269 patients with NIDDM. The patients were divided into two groups depending on the intake of calorie, and PTH and CTN were monitored for 2 years. Plasma levels of vitamin D were measured by competitive protein binding assays before and after each program. The level of PTH (520.8±266.0 pg/ml) (mean±S.D.) was significantly (P<0.01) higher in 109 diabetic patients whose calorie intake was restricted for 2 years (diet (D) group) as compared with that (256.6±103.8 pg/ml) of 160 diabetic patients whose calorie intake was not restricted (non-diet (ND) group). The daily oral calcium intake of the two groups did not differ significantly. We found no significant difference in the serum PTH level in the ND groupVS. normal control subjects (248.8±98.4, N=78). The serum calcium concentration and the amount of calcium excreted in urine were slightly but significantly (P<0.01) lower in the D than in the ND group. The rate of tubular reabsorption of phosphate (% TRP) was significantly lower in the D group than that in the ND group (P<0.01). The serum CTN level was significantly (P<0.01) lower in the D group (33.9±11.3 pg/ml) than in the ND group (64.9±21.2 pg/ml) 2 years after each treatment. The plasma 1,25-(OH)₂-vitamin D level was significantly (P<0.01) lower in the D group (22.2±6.6 pg/ml) than in the ND group (50.6±4.2 pg/ml). When the restriction of calorie intake in the D group was canceled, their PTH levels decreased, which was accompanied by increase in the 1,25-(OH)₂-vitamin D levels, whereas their CTN levels were unchanged. These observations suggested that a restricted calorie intake is a risk factor for secondary hyperparathyroidism as well as for a low serum level of CTN in patients with NIDDM.     

乐脂平治疗Ⅱ型糖尿病高脂血症的临床研究

观察了３０例伴有高脂血症的Ⅱ型糖尿病患者用小剂量乐脂平（５００ｍｇ／ｄ）治疗４周后血清脂质、脂蛋白的变化。结果：血总胆固醇、甘油三酯及极低密度脂蛋白—胆固醇水平较治疗前下降，高密度脂蛋白—胆固醇明显升高，血糖、血肌酐及血尿酸无明显变化。服用该药未观察到不良反应，提示乐脂平能较好地改善糖尿病患者的脂代谢紊乱。     

舒降之治疗老年人高脂血症的疗效观察

目的：观察舒降之（辛伐他汀）20mg每日一次降脂的临床疗效。方法：选35例老年高脂血症患者接受舒降之20mg,每日1次（晚上顿服）治疗,疗程8周。观察治疗前后血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）。结果：治疗8周后,血清TC、TG、LDL-C较入组前分别降低了29.20%、24.75%、32.87%（均P〈0.01）,其中,降低TC的总有效率为93.54%、降低TG的总有效率为59.26%。HDL-C较入组前升高了14.12%（P〈0.01）,升高HDL-C的总有效率为54.54%。结论：舒降之20mg,每日1次服用,安全有效,对改善老年人高脂血症有显著疗效。